Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells

被引:38
作者
Günthert, AR [1 ]
Gründker, C [1 ]
Hollmann, K [1 ]
Emons, G [1 ]
机构
[1] Univ Gottingen, Dept Gynecol & Obstet, D-37075 Gottingen, Germany
关键词
LHRH; GnRH; ovarian cancer; JunD; cell cycle; DNA synthesis;
D O I
10.1016/S0006-291X(02)00427-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Expression of luteinizing hormone-releasing hormone (LHRH) and its receptor as part of an autocrine regulatory system of cell proliferation has been demonstrated in a number of human malignant tumors, including cancers of the ovary. This study was conducted to investigate whether LHRH induces activation of JunD and affects cell cycle regulation and DNA synthesis. Treatment of primary human ovarian cancer cells and human ovarian cancer cell lines EFO-21 and EFO-27 with LHRH agonist triptorelin (100 nM) resulted in an increase in G(0/1) phase and a decrease in G2/s phase of cell cycle. Treatment of quiescent EFO-21 or EFO-27 cells with triptorelin (100 nM) resulted in a 46.7 or 44.2-fold increase of AP-1 activation, respectively (p < 0.001). Maximal binding of JunD on DNA consensus sequence was found after 4 h of treatment of quiescent EFO-21 or EFO-27 cells with triptorelin (100 nM). DNA synthesis was significantly decreased to 45.5 +/- 11.4% (day 0 = control = 100%; p < 0.001) after 3 days of triptorelin (1 nM) treatment. These results suggest that LHRH agonist triptorelin induces JunD-DNA binding, resulting in reduced proliferation as indicated by increased G(0/1) phase of cell cycle and decreased DNA synthesis. Since LHRH activates nucleus factor kappa B (NFkappaB) and protects ovarian cancer cells from doxorubicin-induced apoptosis and JunD is shown to decrease cell cycle and cell proliferation, we propose that JunD activated by LHRH acts as a modulator of cell proliferation and cooperates with the antiapoptotic and anti-mitogenic functions of LHRH. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:11 / 15
页数:5
相关论文
共 50 条
  • [11] Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells
    Günthert, AR
    Gründker, C
    Böttcher, B
    Emons, G
    ANTICANCER RESEARCH, 2004, 24 (3A) : 1727 - 1732
  • [12] Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells
    Culig, Z
    Hobisch, A
    Hittmair, A
    Cronauer, MV
    Radmayr, C
    Zhang, J
    Bartsch, G
    Klocker, H
    PROSTATE, 1997, 32 (02) : 106 - 114
  • [13] Dephosphorylation of Cancer Protein by Tyrosine Phosphatases in Response to Analogs of Luteinizing Hormone-releasing Hormone and Somatostatin
    Lee, Lung-Ta
    Schally, Andrew V.
    Liebow, Charles
    Lee, Ping-Ping
    Lee, Po-Huang
    Lee, Ming-Ting
    ANTICANCER RESEARCH, 2008, 28 (5A) : 2599 - 2605
  • [14] Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell tines independent of multidrug resistance-1 (MDR-1) system
    Günthert, AR
    Gründker, C
    Bongertz, T
    Schlott, T
    Nagy, A
    Schally, AV
    Emons, G
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (04) : 1164 - 1172
  • [15] Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207
    Arencibia, JM
    Bajo, AM
    Schally, AV
    Krupa, M
    Chatzistamou, I
    Nagy, A
    ANTI-CANCER DRUGS, 2002, 13 (09) : 949 - 956
  • [16] Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice
    Gründker, C
    Völker, P
    Griesinger, F
    Ramaswamy, A
    Nagy, A
    Schally, AV
    Emons, G
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (03) : 528 - 537
  • [17] CORTICOTROPIN-RELEASING HORMONE, LUTEINIZING-HORMONE-RELEASING HORMONE, GROWTH HORMONE-RELEASING HORMONE, AND SOMATOSTATIN-LIKE IMMUNOREACTIVITIES IN BIOPSIES FROM BREAST-CANCER PATIENTS
    CIOCCA, DR
    PUY, LA
    FASOLI, LC
    TELLO, O
    AZNAR, JC
    GAGO, FE
    PAPA, SI
    SONEGO, R
    BREAST CANCER RESEARCH AND TREATMENT, 1990, 15 (03) : 175 - 184
  • [18] Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix
    Siejka, Agnieszka
    Schally, Andrew V.
    Block, Norman L.
    Barabutis, Nektarios
    BJU INTERNATIONAL, 2010, 106 (09) : 1382 - 1388
  • [19] Synthesis and in vitro anti-cancer evaluation of luteinizing hormone-releasing hormone-conjugated peptide
    Deng, Xin
    Qiu, Qianqian
    Ma, Ke
    Huang, Wenlong
    Qian, Hai
    AMINO ACIDS, 2015, 47 (11) : 2359 - 2366
  • [20] Ability of luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHRH receptor on human liver cancer cells
    Shou-Liang Gong Gang Zhao Hong-Guang Zhao Wen-Tian Lü Guang-Wei Liu Ping Zhu Radiobiology Research Unit of Ministry of Public Health
    World Journal of Gastroenterology, 2004, (19) : 2870 - 2873